Prozymi Biolabs is a technology company.
Prozymi Biolabs has raised $200K across 1 funding round.
Prozymi Biolabs has raised $200K in total across 1 funding round.
# High-Level Overview
Prozymi Biolabs is a biotechnology startup developing enzyme-based solutions to degrade gluten proteins, enabling the production of gluten-safe foods using traditional wheat flour[1][2]. Founded in early 2021 and based at Roslin Innovation Centre in Midlothian, Scotland, the company addresses a significant market opportunity: the global demand for gluten-free products that match the taste, texture, and nutritional profile of conventional bread[2][5].
The company serves food manufacturers, breweries, and pharmaceutical companies seeking to produce gluten-safe products without compromising quality or sustainability[2][5]. By isolating natural enzymes from bacteria that degrade gliadin—the immunogenic protein in gluten that triggers celiac disease and gluten sensitivity—Prozymi enables producers to use locally sourced wheat instead of imported gluten-free flour blends[4][5]. This approach delivers tangible benefits: improved texture and nutritional content, reduced costs, and lower carbon emissions compared to existing gluten-free alternatives[5].
# Origin Story
Prozymi Biolabs was founded in February 2021 by Dr. Ioannis Stasinopoulos and Dr. Andreas Andreou, both based in Edinburgh[3][4]. The idea emerged from a practical research approach: Andreou collected varieties of wheat and barley to identify microorganisms capable of degrading gluten as a nitrogen source[4]. Through plate assays and genetic analysis, the team screened bacterial and fungal enzymes, discovering natural candidates suitable for enzymatic degradation of gliadins[4].
The company experienced rapid early traction, securing selection into multiple prestigious accelerator programs including IBioIC's Biotech Innovators incubator, University of Edinburgh's Venture Builder Incubator, Barclays' AgriTech Bridge program, and Carbon 13 Venture Launchpad[2]. These partnerships strengthened their R&D capabilities through collaborations with the University of Edinburgh's Proteomics and Metabolomics facility and Edinburgh Genome Foundry, establishing a pipeline for screening and expressing gluten-degrading enzymes[2].
# Core Differentiators
# Role in the Broader Tech Landscape
Prozymi operates at the intersection of synthetic biology, food technology, and health-conscious consumer trends. The company rides several converging forces: growing celiac disease awareness, consumer demand for sustainable food production, and the limitations of existing gluten-free alternatives that sacrifice taste and nutrition[2][5].
The timing is favorable. The global gluten-free market is expanding due to increased diagnosis of gluten-related disorders, yet current solutions rely on expensive, environmentally costly imported ingredients[2]. Enzymatic solutions represent a paradigm shift—rather than avoiding gluten entirely, they neutralize its immunogenic properties while preserving traditional food quality. This positions Prozymi within the broader biotech trend of using precision enzymes to solve food industry challenges, similar to how enzyme engineering has transformed brewing and dairy production.
The company also benefits from Scotland's strong biotech ecosystem, with access to university research infrastructure and venture support networks that accelerate development cycles and reduce costs[2].
# Quick Take & Future Outlook
Prozymi Biolabs is well-positioned to capture meaningful market share in the gluten-free food sector, but faces the typical biotech challenge of scaling enzyme production from laboratory discovery to commercial viability. The next critical milestone is optimizing microbial fermentation systems for large-scale production[4]—a technical hurdle that will determine whether the company can meet demand from major food manufacturers.
The company's intellectual property strategy—patenting both the enzymes themselves and novel product formulations—suggests ambitions beyond licensing to establish direct commercial products[4]. If successful, Prozymi could reshape how the food industry approaches gluten management, moving from avoidance to enzymatic remediation. This shift would have ripple effects across baking, brewing, and potentially pharmaceutical applications for celiac disease management.
The broader trend favoring them: consumer preference for "clean label" solutions that improve rather than replace traditional ingredients, combined with regulatory tailwinds around enzyme use in food production. As major baking companies seek competitive differentiation in the gluten-free category, Prozymi's technology offers a defensible, science-backed advantage that could become industry standard.
Prozymi Biolabs has raised $200K in total across 1 funding round.
Prozymi Biolabs's investors include 18.Ventures, Alumni Ventures, Astanor Ventures, Babel Ventures, Big Idea Ventures, Capital V, Craig Shapiro, Social Starts.
Prozymi Biolabs has raised $200K across 1 funding round. Most recently, it raised $200K Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $200K Seed | 18.Ventures, Alumni Ventures, Astanor Ventures, Babel Ventures, Big Idea Ventures, Capital V, Craig Shapiro, Social Starts |